object
studi
compar
effect
nongmo
saccharomyc
cerevisia
ferment
product
scfp
halofuginon
treatment
cryptosporidium
parvum
infect
prewean
calv
commerci
dairi
farm
total
neonat
femal
calv
hous
individu
hutch
enrol
sequenti
base
date
birth
block
anim
calv
within
block
alloc
one
treatment
remain
untreat
fed
scfp
diamond
v
smartcar
gd
milk
nutritek
gd
starter
grain
first
day
life
treat
halofuginon
mgkgd
first
day
life
fecal
sampl
collect
day
postpartum
examin
cryptosporidium
oocyst
coproantigen
presenc
intens
diarrhea
monitor
score
daili
first
week
life
calv
weigh
day
age
almost
calv
cryptosporidiumposit
least
studi
halofuginon
significantli
reduc
number
cryptosporidiumposit
fecal
sampl
compar
two
group
base
coproantigen
score
halofuginon
scfp
feed
significantli
reduc
intens
cryptosporidium
infect
compar
untreat
group
diarrhea
record
almost
calv
least
neither
proport
diarrheic
calv
intens
durat
diarrhea
differ
among
treatment
group
significantli
mean
daili
weight
gain
first
week
life
significantli
lower
halofuginon
treat
calv
group
howev
end
studi
period
total
weight
gain
significantli
differ
among
treatment
group
conclus
clinic
result
weight
gain
prewean
supplement
scfp
neither
better
wors
halofuginon
treatment
suggest
scfp
feed
may
clinic
point
view
natur
altern
measur
instead
halofuginon
treatment
bovin
cryptosporidiosi
cryptosporidium
speci
minut
protozoan
pathogen
vertebr
mammal
includ
man
bird
reptil
fish
amphibian
worldwid
occurr
fayer
deplaz
et
al
belong
phylum
apicomplexa
recent
reclassifi
coccidian
gregarin
parasit
cavaliersmith
thompson
et
al
cryptosporidium
spp
known
present
genotyp
b
bovin
type
c
parvum
complex
major
enteropathogen
neonat
calv
broglia
et
al
feng
et
al
holzhausen
et
al
cryptosporidium
spp
direct
life
cycl
brief
infect
host
shed
infecti
oocyst
fece
new
host
becom
infect
oral
ingest
oocyst
hosttohost
rout
environ
via
oocystcontamin
drink
water
food
mammal
cryptosporidium
spp
primarili
infect
intestin
epithelium
parasit
microvil
brush
border
enterocyt
endogen
life
cycl
includ
first
asexu
multipl
merogoni
follow
sexual
develop
gamogoni
second
asexu
multipl
sporogoni
result
huge
quantiti
infecti
oocyst
shed
fece
oocyst
remain
viabl
infecti
environ
month
fayer
deplaz
et
al
cryptosporidium
infect
common
endem
mani
cattl
farm
worldwid
especi
larg
dairi
enterpris
joachim
et
al
trotzwilliam
et
al
al
mawli
et
al
delafoss
et
al
niin
et
al
uri
et
al
b
c
parvum
one
four
main
caus
diarrhea
calv
within
first
week
life
gillhub
et
al
al
mawli
et
al
anonym
calv
becom
infect
within
first
day
life
infect
may
caus
clinic
symptom
often
respons
wateri
diarrhea
acut
onset
accompani
depress
weak
anorexia
diseas
result
sever
villou
atrophi
small
intestin
cryptosporidiumcaus
diarrhea
gener
last
sever
day
selflimit
develop
immun
thomson
et
al
cryptosporidium
spp
less
complet
insensit
usual
anticoccidi
drug
effect
eimeria
spp
coccidian
parasit
anim
stockdal
et
al
shahiduzzaman
daugschi
possibl
gregarin
charact
two
compound
use
field
found
anticryptosporidi
effect
calv
oral
administr
sever
day
treatment
start
first
day
life
halofuginon
et
al
de
wael
et
al
trotzwilliam
et
al
almawli
et
al
niin
et
al
paromomycin
fayer
elli
grinberg
et
al
halofuginon
drug
approv
cryptosporidium
use
neonat
calv
author
europ
anonym
howev
metaanalysi
result
respect
studi
conclud
benefici
effect
found
use
halofuginon
prophylact
treatment
cryptosporidiosi
substanc
toxic
use
sever
c
parvumassoci
diarrhoeal
problem
et
al
recent
studi
halofuginon
given
prophylact
result
reduc
oocyst
shed
improv
clinic
symptom
bodyweight
gain
calv
compar
untreat
control
trotzwilliam
et
al
almawli
et
al
even
neg
associ
weight
gain
niin
et
al
report
recent
feed
neonat
cryptosporidiuminfect
calv
saccharomyc
cerevisia
ferment
product
result
significantli
less
fragment
atrophi
villi
lower
small
intestin
comparison
untreat
control
suggest
prevent
effect
product
infect
flore
et
al
therefor
present
longitudin
cohort
studi
perform
determin
parasitolog
clinic
econom
effect
cerevisia
ferment
product
cryptosporidium
infect
neonat
calv
comparison
posit
halofuginon
treat
neg
untreat
control
group
studi
perform
commerci
dairi
cow
farm
approxim
cow
eastern
germani
decemb
april
farm
known
harbor
cryptosporidium
infect
endem
halofuginon
prophylact
use
past
total
femal
calv
holstein
frisian
breed
healthi
day
birth
respect
studi
day
enrol
studi
feed
manag
practic
follow
routin
procedur
farm
calv
immedi
separ
dam
birth
identifi
number
ear
tag
hous
outdoor
individu
hutch
concret
floor
suppli
straw
bed
first
week
life
calf
given
approxim
l
colostrum
dam
within
first
h
birth
thereaft
fed
whole
wast
milk
twice
day
nd
week
life
addit
grain
offer
ad
libitum
consumpt
calv
primipar
secundipar
multipar
cow
cow
lactat
respect
secundiand
multipar
dam
vaccin
rotaviru
coronaviru
infect
birth
calv
primipar
dam
get
vaccin
follow
farm
practic
two
scerevisia
fermentationbas
nongmo
feed
addit
scfp
smartcar
nutritek
suppli
diamond
v
product
store
room
temperatur
given
accord
manufactur
instruct
g
smartcarecalfday
mix
milk
given
oral
g
nutritekcalfday
mix
small
amount
starter
feed
offer
directli
feed
time
day
day
halofuginon
halo
halocur
mgml
msd
tiergesundheit
germani
given
accord
manufactur
instruct
calv
kg
kg
birth
weight
receiv
ml
ml
halocur
respect
lighter
heavier
calv
receiv
ml
halocur
kg
correspond
dose
rate
mg
halofuginonekg
drug
oral
administ
use
dispens
daili
morn
feed
day
studi
calv
sequenti
enrol
block
anim
base
date
birth
calv
within
block
alloc
one
treatment
remain
untreat
con
fed
scfp
treat
halo
alloc
calf
suffer
diseas
diarrhea
first
week
life
well
calv
block
remov
studi
replac
new
block
calv
calv
weigh
use
scale
day
birth
well
day
calf
examin
daili
inspect
clinic
symptom
morn
throughout
studi
period
blood
sampl
collect
calf
punctur
vena
jugulari
day
serum
isol
centrifug
store
examin
total
fecal
sampl
rectal
collect
calf
morn
day
label
kept
examin
consist
fecal
sampl
estim
score
solid
score
semiliquid
wateri
joachim
et
al
two
four
calv
die
studi
necropsi
extern
laboratori
determin
efficaci
passiv
transfer
immun
serum
total
protein
concentr
gl
estim
use
hand
refractomet
weaver
et
al
neg
carbolfuchsin
fecal
smear
stain
method
use
detect
cryptosporidium
oocyst
hein
potter
van
esbroeck
fecal
sampl
day
intens
oocyst
shed
estim
score
score
accord
castrohermida
et
al
detect
cryptosporidium
spp
coproantigen
commerci
avail
immunochromatograph
insitu
rapid
diagnost
kit
smartstrip
cryptosporidiumbio
combin
smartstrip
app
biox
diagnost
rochefort
belgium
use
accord
manufactur
instruct
test
allow
semiquantit
estim
intens
cryptosporidium
infect
score
score
molecular
character
cryptosporidium
speci
c
parvum
genotyp
present
farm
dna
isol
oocystposit
fecal
sampl
differ
calv
use
qiaamp
dna
stool
kit
qiagen
gmbh
hilden
germani
accord
protocol
smallsubunit
ribosom
rna
ssu
rrna
gene
partial
amplifi
pcr
restrict
fragment
length
polymorph
rflp
analysi
perform
describ
xiao
et
al
identifi
c
parvum
subtyp
dna
isol
bpfragment
glycoprotein
gene
amplifi
nest
pcr
use
primer
first
pcr
second
pcr
describ
sulaiman
et
al
amplicon
purifi
directli
sequenc
use
primer
second
pcr
extern
servic
provid
lgc
genom
gmbh
berlin
germani
sequenc
obtain
assembl
blast
search
http
blastncbinlmnihgovblast
cgi
genbank
databas
perform
subtyp
c
parvum
design
accord
nomenclatur
describ
sulaiman
et
al
e
number
tandem
trinucleotid
repeat
tca
tcg
g
tct
code
amino
acid
serin
number
repeat
acatca
r
immedi
nucleotid
triplet
qualit
detect
rotaviru
coronaviru
andor
e
coli
coproantigen
fecal
sampl
day
commerci
avail
immunochromatograph
rapid
diagnost
kit
rainbow
calf
scoursbio
biox
diagnost
rochefort
belgium
use
accord
manufactur
instruct
day
fecal
sampl
calf
qualit
examin
eimeria
spp
giardia
sp
parasit
stage
eg
entamoeba
cyst
strongyloid
egg
use
modifi
formalineth
sediment
techniqu
young
et
al
addit
giardia
spp
coproantigen
commerci
avail
qualit
enzym
immunoassay
prospect
giardia
micropl
assay
virotech
diagnost
gmbh
germani
use
accord
manufactur
instruct
statist
analys
perform
use
statist
program
packag
bmdp
dixon
bia
ackermann
descript
paramet
respect
arithmet
mean
standard
deviat
minimum
maximum
calcul
differ
detect
pathogen
treatment
group
analyz
signific
use
chi
test
dichotom
nomin
scale
variabl
kruskalw
test
bonferroni
correct
dunn
posttest
ordin
scale
paramet
get
global
basi
evalu
intens
cryptosporidium
infect
estim
use
area
curv
auc
oocyst
shed
coproantigen
score
time
first
step
auc
respect
score
calcul
calf
day
second
step
statist
comparison
done
individu
auc
valu
use
oneway
analysi
covari
repeat
measur
respect
treatment
group
group
number
parturit
cow
covari
case
overal
signific
differ
pairwis
comparison
treatment
follow
use
studentnewmankeulstest
addit
auc
analysi
oocyst
coproantigen
score
twoway
analysi
covari
repeat
measur
respect
treatment
group
day
observ
group
number
parturit
cow
covari
done
score
metric
scale
normal
distribut
result
must
seen
exploratori
one
aim
addit
comparison
examin
time
effect
correl
analys
done
analyz
relationship
number
day
diarrhea
serum
total
protein
concentr
well
auc
valu
cryptosporidium
oocyst
shed
coproantigen
score
kappa
statist
calcul
assess
agreement
result
two
method
use
detect
cryptosporidium
infect
addit
correl
score
result
method
evalu
use
spearman
rank
correl
coeffici
r
respect
scale
paramet
statist
test
twotail
differ
effect
pvalu
consid
signific
studi
calv
born
primipar
secundipar
multipar
cow
averag
lactat
number
cow
differ
significantli
among
treatment
group
p
serum
total
protein
concentr
day
reach
exceed
valu
gl
calv
calv
gl
gl
respect
influenc
number
parturit
dam
differ
significantli
among
treatment
group
con
gl
scfp
gl
halo
gl
cryptosporidium
speci
isol
differ
calf
fecal
sampl
identifi
pcrrflp
analysi
c
parvum
genotyp
b
base
gene
isol
belong
subtyp
fecal
sampl
examin
result
posit
vs
neg
coproantigen
immunochromatographi
substanti
agre
carbolfuchsin
fecal
smear
stain
kappa
valu
confid
interv
rel
sensit
rel
specif
stain
method
respect
employ
immunochromatographi
rel
gold
standard
score
result
method
highli
correl
r
p
almost
studi
calv
regardless
treatment
group
shed
cryptosporidium
oocyst
posit
coproantigen
least
first
week
life
tabl
total
fecal
sampl
examin
day
posit
oocyst
coproantigen
respect
number
oocystand
coproantigenposit
fecal
sampl
treatment
group
differ
significantli
p
p
respect
significantli
lower
halo
treat
calv
con
p
p
respect
scfp
fed
calv
p
p
respect
signific
differ
con
scfp
tabl
cryptosporidium
oocyst
coproantigen
first
detect
fece
day
respect
trend
later
onset
oocyst
shed
coproantigen
posit
halo
treat
calv
treatment
group
tabl
individu
durat
oocyst
shed
coproantigen
posit
rang
day
day
respect
without
signific
differ
among
treatment
group
tabl
auc
valu
oocyst
shed
coproantigen
score
time
use
estim
intens
cryptosporidium
infect
overal
comparison
auc
valu
show
signific
differ
among
treatment
group
oocyst
shed
p
coproantigen
p
subsequ
pairwis
comparison
auc
valu
oocyst
shed
score
significantli
lower
halo
treat
calv
time
p
con
one
auc
valu
coproantigen
score
significantli
lower
halo
treat
time
p
scfp
fed
calv
time
p
con
one
tabl
twoway
analysi
covari
show
signific
effect
age
cow
first
parturit
vs
second
parturit
first
parturit
vs
parturit
cryptosporidium
oocyst
shed
score
howev
mean
oocyst
shed
score
significantli
associ
treatment
p
time
p
signific
treatment
time
interact
p
impli
overal
averag
score
differ
among
treatment
group
score
vari
calv
age
score
curv
con
scfp
similar
start
earlier
ran
higher
halo
fig
howev
overal
mean
auc
scfp
halo
similar
tabl
similar
result
obtain
coproantigen
score
data
shown
statist
signific
correl
auc
valu
cryptosporidium
oocyst
shed
score
r
p
coproantigen
score
r
p
calf
serum
total
protein
concentr
measur
day
rotaviru
coronaviru
ecoli
coproantigen
found
least
respect
calv
respect
fecal
sampl
examin
day
signific
differ
among
treatment
group
tabl
valu
paramet
superscript
column
significantli
differ
p
day
day
birth
last
day
fecal
examin
respect
arithmet
mean
standard
deviat
minimummaximum
valu
differ
superscript
column
significantli
differ
p
p
oocyst
coproantigen
respect
arithmet
mean
standard
deviat
four
calv
diarrhea
die
studi
period
mortal
one
calf
treatment
group
con
scfp
day
day
respect
two
halo
treat
calv
day
scfp
calf
one
halo
calv
postmortem
examin
extern
laboratori
patholog
diagnosi
bacteriaandor
viruscaus
enter
candidacaus
enter
respect
diarrhea
diagnos
sampl
solid
consist
occur
calv
least
day
total
fecal
sampl
show
semiliquid
wateri
consist
treatment
group
differ
significantli
diarrhea
last
day
averag
tabl
major
fecal
sampl
alter
consist
seen
day
fig
number
day
diarrhea
significantli
correl
serum
total
protein
concentr
day
r
p
auc
valu
number
day
diarrhea
differ
significantli
among
treatment
group
tabl
intens
cryptosporidium
infect
measur
individu
mean
auc
valu
coproantigen
score
significantli
correl
number
day
diarrhea
day
r
p
higher
auc
valu
day
diarrhea
observ
mean
oocyst
shed
correl
statist
signific
r
p
individu
birth
weight
calv
rang
kg
mean
valu
differ
significantli
p
among
treatment
group
tabl
highli
signific
group
differ
daili
weight
gain
first
week
life
p
halo
treat
calv
significantli
lower
averag
daili
gain
adg
scfp
fed
p
con
calv
p
signific
differ
scfp
con
calv
howev
signific
differ
adg
observ
among
treatment
group
rest
studi
period
end
studi
period
individu
total
weight
gain
rang
kg
adg
g
slightli
significantli
lower
halo
treat
calv
calv
treatment
group
tabl
day
calv
examin
posit
eimeria
mainli
e
bovi
oocyst
giardia
cyst
coproantigen
entamoeba
cyst
without
signific
differ
among
treatment
group
stage
parasit
found
valu
respect
coproantigen
superscript
column
significantli
differ
p
number
posit
calv
samplestot
number
calv
sampl
fig
cours
mean
fecal
consist
score
score
solid
semiliquid
wateri
calv
treat
halofuginon
day
halo
daili
fed
cerevisia
ferment
product
day
scfp
remain
untreat
con
current
halofuginon
drug
approv
author
europ
use
newborn
calv
cryptosporidium
infect
howev
prophylact
effect
cryptosporidiosi
equivoc
et
al
therefor
demand
altern
result
experiment
studi
suggest
reduct
histopatholog
alter
small
intestin
caus
cryptosporidium
calv
scfp
fed
flore
et
al
present
longitudin
studi
perform
evalu
first
time
field
condit
effect
longterm
feed
two
nongmo
scfp
cryptosporidium
infect
neonat
calv
comparison
prophylact
halo
treat
untreat
group
main
result
halo
treatment
show
partial
anticryptosporidi
activ
signific
clinic
effect
find
record
scfp
feed
word
neither
better
wors
halo
treatment
calv
enrol
studi
similar
histori
femal
herd
breed
kept
manag
condit
receiv
basic
feed
age
dam
differ
significantli
among
treatment
group
therefor
impact
age
dam
serum
total
protein
concentr
intens
cryptosporidium
infect
estim
auc
valu
oocyst
shed
coproantigen
score
intens
diarrhea
estim
auc
valu
number
day
diarrhea
respect
calv
almost
calv
serum
total
protein
concentr
reach
exceed
valu
gl
day
regardless
treatment
group
indic
suffici
transfer
immunoglobulin
colostrum
calv
weaver
et
al
princip
necessari
protect
calv
morbid
uri
et
al
therefor
surpris
serum
total
protein
concentr
correl
intens
cryptosporidium
infect
measur
auc
valu
oocyst
shed
coproantigen
score
number
day
diarrhea
studi
cryptosporidium
infect
diagnos
almost
calv
treatment
group
untreat
control
calv
nearli
half
fecal
sampl
collect
first
week
life
posit
oocyst
coproantigen
contrast
coinfect
enteropathogen
rotaviru
coronaviru
e
coli
detect
smaller
number
calv
posit
one
day
result
posit
fecal
sampl
accord
result
previou
studi
eg
gillhub
et
al
al
mawli
et
al
anonym
therefor
cryptosporidium
consid
main
enteropathogen
respons
episod
diarrhea
present
studi
untreat
calv
cryptosporidium
oocyst
shed
start
day
birth
averag
accord
previou
field
observ
eg
castrohermida
et
al
niin
et
al
uri
et
al
also
similar
data
experiment
infect
zambriski
et
al
show
studi
calv
becam
infect
shortli
birth
speci
identifi
c
parvum
genotyp
b
subtyp
commonli
found
neonat
calv
germani
broglia
et
al
holzhausen
et
al
elsewher
feng
et
al
sensit
direct
fecal
smear
stain
lower
compar
coproantigen
detect
method
use
gold
standard
find
alreadi
report
previous
eg
chartier
et
al
howev
result
method
substanti
agre
indic
fecal
smear
stain
use
simpl
fast
inexpens
method
cryptosporidium
diagnosi
least
endem
infect
cattl
farm
prophylact
halo
treatment
neither
prevent
cryptosporidium
infect
reduc
number
cryptosporidiumposit
calv
howev
halo
treatment
result
signific
reduct
number
cryptosporidiumposit
fecal
sampl
compar
con
scfp
fed
calv
also
trend
signific
later
onset
oocyst
coproantigen
posit
halo
treat
calv
two
group
final
intens
cryptosporidium
infect
estim
auc
valu
oocyst
shed
coproantigen
score
significantli
reduc
halo
group
comparison
con
scfp
result
indic
fulli
prophylact
anticryptosporidi
effect
halo
alreadi
observ
previou
studi
eg
et
al
trotzwilliam
et
al
delafoss
et
al
niin
et
al
daili
feed
two
scfp
week
reduc
neither
number
cryptosporidiumposit
calv
number
posit
fecal
sampl
also
delay
onset
shorten
durat
oocyst
coproantigen
posit
comparison
con
howev
interest
note
intens
infect
estim
auc
valu
coproantigen
score
oocyst
shed
score
significantli
lower
scfp
fed
calv
con
one
find
may
indic
although
partial
effect
scfp
endogen
multipl
cryptosporidium
possibl
result
modifi
intestin
environ
assum
correct
reduc
endogen
multipl
parasit
would
result
less
patholog
alter
intestin
mucosa
correspond
histolog
find
flore
et
al
albeit
obvious
without
clinic
improv
context
interest
mention
scfp
shown
posit
effect
intestin
develop
prewean
calv
xiao
et
al
posit
immunomodulatori
effect
anim
park
chou
et
al
cours
warrant
investig
mechan
action
scfp
present
studi
rel
low
daili
weight
gain
rang
g
group
averag
record
end
period
may
neg
consequ
diarrheal
episod
first
sever
week
life
less
calv
number
diarrheal
day
significantli
correl
intens
cryptosporidium
infect
indic
parasit
respons
diarrhea
present
studi
contrast
consider
higher
adg
g
averag
wean
age
day
report
dairi
calv
largescal
us
studi
howev
clinic
sign
seen
anim
includ
digest
sign
uri
et
al
although
halo
treatment
show
partial
anticryptosporidi
activ
clinic
effect
present
studi
significantli
affect
onset
frequenc
durat
intens
diarrhea
main
clinic
symptom
cryptosporidiosi
result
consist
observ
previou
studi
report
nonsignific
associ
prophylact
use
incid
durat
intens
diarrhea
et
al
trotzwilliam
et
al
almawli
et
al
meganck
et
al
find
record
scfp
feed
word
neither
better
wors
halo
treatment
nonsignific
differ
weight
gain
halo
treat
con
calv
report
other
trotzwilliam
et
al
recent
studi
halo
treatment
even
neg
effect
daili
weight
gain
month
niin
et
al
stress
present
studi
halo
treatment
clearli
result
neg
impact
weight
gain
first
week
life
compar
scfp
con
calv
temporarili
insuffici
weight
develop
explain
known
toxic
halo
induc
revers
gastrointestin
inflammatori
necrot
lesion
also
therapeut
dose
anonym
calv
treatment
group
posit
eimeria
spp
oocyst
giardia
andor
entamoeba
cyst
week
age
patent
eimeria
infect
occasion
seen
age
week
still
consid
clinic
inappar
eg
faber
et
al
sever
eimeria
infect
first
observ
older
grouphous
calv
niin
et
al
may
result
morbid
bangoura
et
al
giardia
spp
infect
common
cattl
farm
worldwid
calv
usual
becom
infect
th
week
life
preval
peak
report
old
anim
geurden
et
al
geurden
et
al
gillhub
et
al
niin
et
al
uri
et
al
giardia
spp
seem
abl
induc
diarrhea
gillhub
et
al
may
reduc
weight
gain
uri
et
al
mainli
calv
older
one
month
entamoeba
bovi
infect
uncommon
cattl
consid
less
pathogen
matsubayashi
et
al
prewean
supplement
two
cerevisia
ferment
feed
addit
show
similar
clinic
result
weight
gain
cryptosporidium
infect
newborn
calv
halofuginon
treatment
condit
farm
suggest
feed
cerevisia
ferment
product
may
clinic
point
view
natur
altern
measur
instead
halofuginon
treatment
bovin
cryptosporidiosi
studi
fund
grant
diamond
v
cedar
rapid
iowa
usa
pz
iy
current
employe
diamond
v
